###### Summary

What is already known on this topic?
====================================

People living with HIV (PLHIV) have greater incidence of comorbidities and higher prevalence of polypharmacy, most commonly defined as taking 5 or more medications concurrently, than the general population.

What is added by this study?
============================

PLHIV reporting polypharmacy had significantly worse overall health outcomes, including significantly lower prevalence of self-reported virologic control and treatment satisfaction. These findings were significant despite controlling for presence of comorbidities.

What are the implications for public health practice?
=====================================================

By actively assessing patients holistically and considering how increased medication may influence individual behavior to health outcomes, clinicians may contribute to improving health-related quality of life among people living with HIV.

Introduction
============

With advances in antiretroviral therapy (ART), the life expectancy of people living with HIV (PLHIV) has increased ([@R1]--[@R4]); nevertheless, they are at higher risk for multiple health disorders ([@R5],[@R6]). As with many other chronic illnesses, HIV management goes beyond drug treatment; holistic care is paramount. In its definition of health, the World Health Organization shifted its focus from diagnosis-focused approaches to ones that highlight the person's positive overall well-being and quality of life across physical, mental, and social domains ([@R7]). This paradigm has also emerged within the HIV community with the incorporation of the "fourth 90," calling for improvements in health-related quality of life. The fourth 90 evolved from the global 90--90--90 targets of the Joint United Nations Programme on HIV/AIDS, which called on health systems to increase diagnosis of HIV, treat a greater number of those diagnosed, and ensure that those being treated achieve viral suppression. ([@R8]).

Focusing entirely on a specific disease reduces the health care provider's ability to personalize care for a person affected by a host of comorbidities. Other than medical care, a person's health is significantly determined by environmental, sociopsychological, and economic factors ([@R9]). Hence, success measured purely by clinical outcomes may not mitigate disease. Delivery of fragmented care to patients affected by multiple conditions, even when based on strict adherence to disease-oriented treatment guidelines, promotes polypharmacy, which may increase likelihood of adverse or even antagonistic treatment effects ([@R10]).

Because PLHIV have more non-AIDS comorbidities, a comprehensive approach is needed to evaluate the relationship between increased medication and overall quality of life. Polypharmacy rates among PLHIV, which range from 23% to 39%, are higher than among HIV-negative populations ([@R11]--[@R15]). Studies have demonstrated associations between polypharmacy and clinical outcomes, including death ([@R16]); however, data are scarce on the relationship between polypharmacy and overall quality of life based on subjective measures of well-being that are important to patients ([@R17], [@R18]), including their experiences, concerns, and treatment priorities. To fill these gaps in knowledge, we used pooled data from 24 countries to examine associations between polypharmacy and self-rated overall health and perceptions of treatment needs.

Methods
=======

Data source
-----------

We conducted a cross-sectional study, Positive Perspectives, from April through August 2019 in 24 countries; 2,112 PLHIV aged 18 to 84 participated. Participating countries and the achieved sample size were United States (n = 400), United Kingdom (n = 123), Australia (n = 120), Canada (n = 120), France (n = 120), Germany (n = 120), Italy (n = 120), Spain (n = 120), Japan (n = 75), Mexico (n = 63), Portugal (n = 60), Brazil (n = 58), Russia (n = 57), Taiwan (n = 55), Netherlands (n = 51), Argentina (n = 50), Austria (n = 50), Chile (n = 50), China (n = 50), Ireland (n = 50), Belgium (n = 50), Poland (n = 50), South Korea (n = 50), and Switzerland (n = 50). To be eligible, respondents had to verify that they were HIV sero-positive and receiving treatment (eg, by presenting their ART prescription or a letter from their medical provider); those not currently on HIV treatment (31.6%) were excluded. Financial incentives (approximately £20 GBP or the local equivalent) were provided to encourage participation. Participants were recruited by using targeted and snowball sampling approaches across multiple platforms and in collaboration with multiple HIV organizations; responses were collected over the web or in person. Adaptive sampling was performed to make the distributions of participants in each country more representative. This study was deemed exempt research by the Pearl Institutional Review Board (no. 18--080622).

Measures
--------

**Polypharmacy**. Polypharmacy has no universal definition ([@R19]); however, one commonly used definition is 5 or more medications concurrently ([@R20]). We defined polypharmacy as taking 5 or more pills a day or taking medicines for 5 or more health conditions. This definition, which distinguishes pills (dosage form of a medicine) from medicines (the actual pharmacologic agent) is conservative inasmuch as a single pill could contain more than 1 medicine, which is likely with ART ([@R21]), and more than 1 medication could be used to treat a single condition. Survey participants were asked their frequency of taking HIV and non-HIV pills and were also shown a detailed list of health conditions to ascertain which ones they were currently taking medicines for. Polypharmacy was assessed independent of the presence of diagnosed comorbidities; for example, people taking 5 or more medications for 1 condition would be classified as reporting polypharmacy, whereas those with 5 or more conditions but taking fewer than 5 medicines would be classified as not reporting polypharmacy.

We created 2 other proxies of polypharmacy: a cognitive marker (perceived overmedication), and a behavioral marker (cut-down attempt). The cognitive proxy asked 6 questions to assess respondents' anxiety regarding 1) short-, medium-, and long-term effects of their current HIV medicines, including long-term side effects; 2) prospect of having to take increasingly more medicines; 3) potential interactions among medications; 4) potential effect on body or body shape; 5) potential effect on overall health and well-being; and 6) unknown long-term effects. People were classified as having a perception of overmedication if they affirmed on at least 5 of these questions that they were worried about their intake of medications.

The behavioral proxy (cut-down attempt) was based on the premise that skipping or completely switching medication for the sole purpose of reducing intake of medicines could indicate a person's real or perceived awareness that their medicine intake was high. People were classified as having made a cut-down attempt if they reported skipping their HIV medicines in the past 30 days because they were concerned about medication side effects or if they completely switched regimens to reduce the number of medicines taken.

**Self-rated overall health and its composite domains**. Participants were asked "How would you describe your \[physical/mental/sexual/overall\] health over the past 4 weeks?" Response options were the same for physical, mental, sexual, and overall health: very poor, poor, neither good nor poor, good, or very good. Self-ratings of good or very good were classified as optimal health on that domain; all other responses were classified as suboptimal.

**Treatment concerns, satisfaction, and aspirations**. PLHIV were classified as being recent initiates, treatment experienced, or very treatment experienced. Recent initiates were PLHIV who had been diagnosed within the past 2 years and were on their first regimen. Very treatment experienced were people who switched ART 4 or more times and stopped the penultimate regimen after less than 1 year because of issues with frequency or severity of side effects, noneffectiveness, or resistance. PLHIV not meeting the definition of very treatment experienced or recent initiates were classified as treatment experienced. The survey further assessed participants' awareness of the number of HIV medicines contained in single pills or medications.

"Treatment satisfaction" and "met treatment needs" were defined with affirmative responses to the following questions: "Overall, how satisfied are you with your current HIV medication?" "When it comes to the management of your HIV treatment, do you feel your main HIV care provider meets your personal needs and takes into account the things that are most important to you?" A pessimistic outlook was an affirmative response to at least one of the following: "HIV will reduce my life span," or "Because of my HIV, I do not plan for my old age."

The survey further asked participants about what they prioritized the most when they started ART and what their current priorities were. A new treatment concern was an issue that was not deemed important by the respondent at ART initiation but was currently considered a treatment priority.

**Self-reported virologic status**. Self-reported virologic control was defined as a response of "undetectable," "suppressed versus detectable," "unsuppressed," "I don't know," or "prefer not to say" to the question "What is your most recent viral load?"

**Demographic characteristics**. Demographic characteristics were age, gender, sexual orientation, geographic region, urbanicity, race, employment status, year of diagnosis, disease duration, and non-HIV comorbidities.

Statistical analyses
--------------------

Descriptive and multivariable analyses were performed to measure the relationships between polypharmacy and measures of overall well-being; subgroup differences were tested with χ^2^ tests. Multivariable logistic regression analyses adjusted for age, duration of disease, geographic region, comorbidities, urbanicity, education, and sexual orientation. We performed stratified analyses among PLHIV reporting virologic control (n = 1,536) and those not reporting virologic control (n = 576). Significance was set at *P* \< .05. All analyses were performed with R Version 3.1.1 (The R Foundation).

Results
=======

A total of 2,112 people completed our survey ([Table 1](#T1){ref-type="table"}). Overall, 70.4% were male, 61.4% were white, 45.1% were men who have sex with men, 30.7% were aged 50 or older, and 23.1% were diagnosed with HIV in the past 2 years. Geographically, 45.6% of the sample were from the European Union, 27.6% were from North America, and 26.8% were from other parts of the world. The percentage reporting optimal health was as follows by the health domain: physical, 58.1%; mental, 56.1%; sexual, 46.8%; and overall, 55.8%; approximately 58.9% had less than 1 non-HIV comorbidity. The most common non-HIV conditions PLHIV reported ever being diagnosed with were mental health disorders, including anxiety and depression (20.6%); hypertension (17.3%); hypercholesterolemia (16.9%); insomnia or other sleep disorders (15.6%); gastrointestinal diseases, including ulcers, reflux, and Crohn's disease (12.5%); anemia (11.5%); liver disease (10.8%); arthritis (9.4%); and lung/respiratory diseases (9.1%).

###### Sociodemographic and Clinical Characteristics of People Living With HIV (N = 2,112) in 24 Countries and Measures of Self-Rated Health, Positive Perspectives Study, 2019[a](#T1FN1){ref-type="table-fn"}

  Variable                                                                  Subjective Measures of Quality of Life, %                               
  ------------------------------------------------------------------------- ------------------------------------------- ------ ------ ------ ------ ------
  **Total**                                                                 2,112                                       55.8   56.1   46.8   58.1   69.6
  **Gender**                                                                                                                                        
  Male                                                                      1,486                                       58.1   56.1   46.6   60.1   72.5
  Female                                                                    571                                         50.1   54.6   46.4   51.1   62.9
  Other                                                                     55                                          54.5   70.9   58.2   78.2   60.0
  **Sexual orientation**                                                                                                                            
  Heterosexual                                                              804                                         48.5   47.1   43.2   48.4   59.0
  Homosexual                                                                1,023                                       61.8   61.4   48.1   65.3   77.8
  Other                                                                     285                                         55.1   62.5   52.6   60.0   70.2
  **Gender/sexual orientation**                                                                                                                     
  Men who have sex with men                                                 953                                         62.4   61.7   48.2   66.3   78.4
  Men who have sex with women                                               420                                         50.7   43.8   44.8   48.8   60.0
  Women who have sex with women                                             58                                          45.8   50.1   41.5   47.2   57.7
  Women who have sex with men                                               369                                         51.7   56.9   43.1   48.3   69.0
  Other/indeterminate                                                       312                                         55.1   62.5   52.6   60.6   69.9
  **Age, y**                                                                                                                                        
  \<50                                                                      1,464                                       57.2   54.1   50.6   59.7   67.6
  ≥50                                                                       648                                         52.8   60.6   38.3   54.6   74.1
  **Year of HIV diagnosis**                                                                                                                         
  2017--2019                                                                488                                         51.8   53.1   46.9   56.4   64.1
  2010--2016                                                                805                                         58.4   55.7   51.6   58.6   70.3
  Before 2010                                                               819                                         55.7   58.4   42.1   58.7   72.2
  **Geographic region**                                                                                                                             
  European Union                                                            964                                         57.5   60.3   51.2   62.8   72.1
  North America                                                             583                                         55.6   50.1   39.5   52.5   71.2
  Other                                                                     565                                         53.3   55.2   46.9   56.1   63.7
  **Home ownership**                                                                                                                                
  Own                                                                       653                                         55.7   56.7   44.7   55.4   72.0
  Rent                                                                      825                                         57.8   57.3   47.9   61.3   70.9
  Other                                                                     634                                         53.3   53.9   47.6   56.8   65.5
  **Urbanicity**                                                                                                                                    
  Metropolitan                                                              1,170                                       57.1   59.4   48.1   61.4   73.0
  Nonmetropolitan                                                           942                                         54.2   52.0   45.2   54.1   65.4
  **Employment status**                                                                                                                             
  Employed                                                                  1,258                                       61.1   58.5   51.2   62.2   72.6
  Unemployed/not in workforce                                               854                                         48.0   52.6   40.4   52.1   65.2
  **Race**                                                                                                                                          
  Nonwhite                                                                  816                                         51.7   54.2   44.6   57.6   63.4
  White                                                                     1296                                        58.4   57.3   48.2   58.5   73.5
  **Comorbidity, no.**                                                                                                                              
  None                                                                      879                                         64.6   58.9   57.1   64.8   72.0
  1                                                                         464                                         59.1   59.5   48.9   65.3   70.9
  ≥2                                                                        769                                         43.8   50.8   33.8   46.2   66.1
  **Comorbidity, type**                                                                                                                             
  None                                                                      879                                         64.6   58.9   57.1   64.8   72.0
  Cardio-hematologic only                                                   177                                         62.1   69.5   53.7   67.8   70.1
  Bone only                                                                 23                                          52.2   69.6   47.8   52.2   56.5
  Neurologic only                                                           151                                         53.6   44.4   43.0   65.6   72.2
  Gastrointestinal only                                                     56                                          55.8   63.5   44.2   57.7   73.1
  Pulmonary only                                                            23                                          73.9   60.9   69.6   78.3   78.3
  Cancer only                                                               15                                          73.3   66.7   53.3   73.3   80.0
  Endocrine/renal only                                                      23                                          60.9   56.5   39.1   56.5   65.2
  Multiple                                                                  765                                         43.8   50.8   33.8   46.2   66.1
  **Concomitant medications**                                                                                                                       
  None                                                                      1,209                                       63.4   59.1   53.8   64.6   71.5
  1                                                                         419                                         55.8   58.0   47.7   60.1   67.1
  ≥2                                                                        484                                         37.0   46.9   28.7   40.3   66.9
  **Antiretroviral therapy, switch history, no. of times**                                                                                          
  None                                                                      562                                         59.6   64.8   55.2   66.0   67.6
  1                                                                         563                                         60.4   51.5   50.8   60.6   69.4
  2                                                                         390                                         49.7   45.6   42.8   46.4   66.7
  3                                                                         235                                         57.4   57.0   44.3   61.3   78.7
  ≥4                                                                        362                                         48.3   60.5   33.7   52.8   70.2
  **Antiretroviral therapy, experience** [c](#T1FN3){ref-type="table-fn"}                                                                           
  Recent initiate                                                           241                                         61.0   67.6   54.4   66     69.7
  Experienced                                                               1,790                                       55.4   54.2   46.1   57.3   70.0
  Very experienced                                                          81                                          50.6   63.0   40.7   53.1   60.5
  **Self-reported viral load**                                                                                                                      
  Unsuppressed/unknown                                                      576                                         49.0   47.6   42.5   46.9   63.7
  Suppressed                                                                1,536                                       58.4   59.3   48.4   62.4   71.8

Participating countries were Argentina, Austria, Australia, Belgium, Brazil, Canada, Chile, China, France, Germany, Ireland, Italy, Japan, Mexico, Netherlands, Poland, Portugal, Russia, South Korea, Spain, Switzerland, Taiwan, United Kingdom, and United States.

Self-rated health as good or very good was classified as optimal; ratings of very poor, poor, or neither good nor poor were classified as suboptimal health.

Recent initiates were people living with HIV (PLHIV) who had been diagnosed within the past 2 years and were on their first regimen. Very treatment experienced were people who switched antiretroviral therapy 4 or more times and stopped the penultimate regimen after less than 1 year because of issues with frequency or severity of side effects, noneffectiveness, or resistance. PLHIV not meeting the definition of very treatment experienced or recent initiates were classified as treatment experienced.

Of all participants, 82.0% reported taking at least one non-HIV pill per day or taking medication currently for at least one non-HIV condition, in addition to their ART. The mean number of pills (HIV and non-HIV combined) per day reported was 4.25 (standard deviation \[SD\], 2.28). By polypharmacy status, average pill count per day was 6.48 (95% confidence interval \[CI\], 6.39--6.57) among people with a report of polypharmacy and 2.63 (95% CI, 2.57--2.69) among those without. Overall prevalence of polypharmacy was 42.1%, and this was highest among the following subgroups: men who have sex with women (50.5%, 211 of 418) compared with men who have sex with men (38.9%, 369 of 949) and women (42.1%, 239 of 568) (*P* \< .001); people aged 50 or older (54.6%, 352 of 645) compared with those younger than 50 (36.5%, 532 of 1,457) (*P* \< .001); people diagnosed with HIV before 2010 (50.3%) compared with those diagnosed between 2017 and 2019 (33.5%, 163 of 487) or between 2010 and 2016 (38.9%, 312 of 802) (*P* \< .001); people living in North America (52.2%, 304 of 582) compared with those living in the European Union (33.6%, 323 of 960) or other regions (45.9%, 257 of 560) (*P* \< .001); people residing in nonmetropolitan areas (45.2%, 424 of 938) compared with metropolitan areas (39.5%, 460 of 1,164) (*P* = .009); and people unemployed or not in the work force (48.1%, 409 of 850) compared with those employed (37.9%, 475 of 1,252) (*P* \< .001) ([Table 2](#T2){ref-type="table"}). Furthermore, prevalence of polypharmacy was 26.8%, 36.8%, and 62.8% among those with 0, 1, or 2 or more non-HIV comorbidities, respectively (*P* \< .001). Results from the 2 proxy definitions for polypharmacy yielded results very similar to those obtained with the more objective count of medications; prevalence was 45.7% with the cognitive proxy (perceived overmedication) and 43.7% with the behavioral proxy (cut-down attempt).

###### Polypharmacy and Perceptions of HIV Medications Among People Living With HIV (N = 2,112) in 24 Countries, Positive Perspectives Study, 2019[a](#T2FN1){ref-type="table-fn"}

  Variable                                            Polypharmacy and Concerns About Medicines, %                                      
  --------------------------------------------------- ---------------------------------------------- ------ ------ ------ ------ ------ ------
  **Total**                                           2,112                                          42.1   75.1   56.6   66.6   48.5   73.1
  **Gender**                                                                                                                            
  Male                                                1,486                                          42.8   77.0   55.7   66.2   46.5   73.9
  Female                                              571                                            42.1   72.7   58.7   67.4   52.5   71.5
  Other                                               55                                             20.4   49.1   60.0   69.1   60.0   69.1
  **Sexual orientation**                                                                                                                
  Heterosexual                                        804                                            48.3   71.0   55.3   66.2   49.1   67.5
  Homosexual                                          1,023                                          38.7   79.9   56.4   67.4   45.7   76.9
  Other                                               285                                            36.5   69.5   60.7   64.9   56.5   75.1
  **Gender/sexual orientation**                                                                                                         
  Men who have sex with men                           953                                            38.9   80.4   56.2   68.3   45.2   77.9
  Men who have sex with women                         420                                            50.5   68.3   53.8   61.0   47.9   63.8
  Women who have sex with women                       58                                             47.0   74.0   56.6   71.5   49.9   71.3
  Women who have sex with men                         369                                            37.9   77.6   58.6   55.2   51.7   63.8
  Other/indeterminate                                 312                                            35.4   68.9   60.9   65.1   57.1   75.0
  **Age, y**                                                                                                                            
  \<50                                                1,464                                          36.5   72.3   57.7   65.9   50.8   70.1
  ≥50                                                 648                                            54.6   81.3   54.2   68.1   43.4   79.9
  **Year of HIV diagnosis**                                                                                                             
  2017--2019                                          488                                            33.5   75.4   58.8   63.7   53.3   72.5
  2010--2016                                          805                                            38.9   73.4   56.3   64.1   49.9   70.1
  Before 2010                                         819                                            50.3   76.6   55.6   70.7   44.2   76.4
  **Geographic region**                                                                                                                 
  European Union                                      964                                            33.6   70.5   55.5   65.5   43.8   73.9
  North America                                       583                                            52.2   80.4   55.6   62.8   49.1   69.8
  Other                                               565                                            45.9   77.3   59.5   72.4   55.9   75.2
  **Home ownership**                                                                                                                    
  Own                                                 653                                            50.5   81.8   55.1   66.9   47.2   75.7
  Rent                                                825                                            38.9   73.8   55.6   66.1   47.6   75.8
  Other                                               634                                            37.4   69.9   59.3   66.9   50.9   67.0
  **Urbanicity**                                                                                                                        
  Metropolitan                                        1,170                                          39.5   73.8   59.0   71.2   49.4   76.3
  Nonmetropolitan                                     942                                            45.2   76.6   53.6   60.8   47.3   69.1
  **Employment status**                                                                                                                 
  Employed                                            1,258                                          37.9   76.1   54.5   63.8   47.5   74.5
  Unemployed/not in workforce                         854                                            48.1   73.7   59.7   70.7   50.0   71.1
  **Race**                                                                                                                              
  Nonwhite                                            816                                            38.9   70.3   60.7   73.2   52.1   70.0
  White                                               1296                                           44.0   78.1   54.0   62.4   46.2   75.1
  **Comorbidity, no.**                                                                                                                  
  None                                                879                                            26.8   70.3   52.7   58     45.1   68.8
  1                                                   464                                            36.8   73.5   55.4   68.5   47.6   73.3
  ≥2                                                  769                                            62.8   81.5   61.8   75.2   52.9   77.9
  **Comorbidity, type**                                                                                                                 
  None                                                879                                            26.8   70.3   52.7   58.0   45.1   68.8
  Cardio-hematologic only                             177                                            39.2   68.4   56.5   68.9   52.0   69.5
  Bone only                                           23                                             34.8   91.3   34.8   65.2   34.8   82.6
  Neurologic only                                     151                                            36.4   72.8   62.9   72.8   49.7   73.5
  Gastrointestinal only                               56                                             25.5   78.8   46.2   61.5   40.4   82.7
  Pulmonary only                                      23                                             43.5   82.6   52.2   69.6   47.8   65.2
  Cancer only                                         15                                             20.0   73.3   40.0   60.0   40.0   80.0
  Endocrine/renal only                                23                                             52.2   78.3   52.2   60.9   34.8   73.9
  Multiple                                            765                                            62.8   81.5   61.8   75.2   52.9   77.9
  **Concomitant medications**                                                                                                           
  None                                                1,209                                          27.6   71.6   52.7   61.5   45.9   70.3
  1                                                   419                                            42.0   75.1   58.7   70.9   48.0   77.8
  ≥2                                                  484                                            78.5   84.6   64.1   74.9   54.9   76.0
  **Switched antiretroviral therapy, no. of times**                                                                                     
  None                                                562                                            19.9   62.8   55.0   62.1   46.1   67.4
  1                                                   563                                            43.7   75.7   52.4   62.7   48.7   67.0
  2                                                   390                                            49.4   77.9   60.5   66.2   54.9   75.4
  3                                                   235                                            44.7   79.6   57.4   71.5   45.5   80.4
  ≥4                                                  362                                            64.4   87.3   60.8   76.8   47.0   84.3
  **Antiretroviral therapy, experience with**                                                                                           
  Recent initiates                                    241                                            19.1   73.4   52.3   59.3   45.6   75.5
  Experienced                                         1,790                                          44.5   74.7   56.7   66.9   48.9   72.1
  Very experienced                                    81                                             56.2   88.9   66.7   80.2   46.9   88.9
  **Self-reported viral load**                                                                                                          
  Unsuppressed/unknown                                576                                            46.8   76.6   54.7   56.2   51.6   71.0
  Suppressed                                          1,536                                          40.3   74.5   57.3   70.4   47.3   73.9

Participating country were Argentina, Austria, Australia, Belgium, Brazil, Canada, Chile, China, France, Germany, Ireland, Italy, Japan, Mexico, Netherlands, Poland, Portugal, Russia, South Korea, Spain, Switzerland, Taiwan, United Kingdom, and United States.

Polypharmacy was defined as taking 5 or more pills per day for HIV or non-HIV conditions, or taking medicines for 5 or more conditions, including HIV.

**Polypharmacy and its association with measures of overall well-being**. PLHIV reporting polypharmacy had worse measures of overall well-being than those not reporting polypharmacy ([Table 3](#T3){ref-type="table"}). Prevalence estimates were as follows for those reporting compared with those not reporting polypharmacy, respectively: optimal overall health (46.6% vs 62.6%, *P* \< .001), optimal mental health (46.9% vs 62.9%, *P* \< .001), optimal sexual health (36.2% vs 54.5%, *P* \< .001), and optimal physical health (44.7% vs 68.1%, *P* \< .001). PLHIV reporting polypharmacy also had lower probability of reporting treatment satisfaction (65.2% vs 73.1%, *P* \< .001), positive outlook (42.5% vs 49.8%, *P* = .001), and virologic control (69.7% vs 75.0%, *P* = .007). Consistent results were seen when analyses were stratified by self-reported virologic status ([Table 3](#T3){ref-type="table"}) ([Figure 1](#F1){ref-type="fig"}).

###### Prevalence of Study Outcomes Among People Living With HIV in 24 Countries[a](#T3FN1){ref-type="table-fn"}, With or Without a Report of Polypharmacy[b](#T3FN2){ref-type="table-fn"}, Stratified by Self-Reported Virologic Control Status[c](#T3FN3){ref-type="table-fn"}, Positive Perspectives Study, 2019

  Outcome                                             Medication-Count--Based Measure of Polypharmacy   Proxy Measure of Polypharmacy                                                                                                           
  --------------------------------------------------- ------------------------------------------------- ------------------------------- --------------------------------------------------- --------------------------------------------------- ---------------------------------------------------
  **All participants (N = 2,112)**                                                                                                                                                                                                              
  Self-rated overall health                           46.6                                              62.6                            0.64 (0.53--0.78)[e](#T3FN5){ref-type="table-fn"}   0.66 (0.55--0.80)[e](#T3FN5){ref-type="table-fn"}   0.66 (0.54--0.80)[e](#T3FN5){ref-type="table-fn"}
  Self-rated mental health                            46.9                                              62.9                            0.58 (0.48--0.71)[e](#T3FN5){ref-type="table-fn"}   0.84 (0.70--1.01)                                   0.50 (0.42--0.61)[e](#T3FN5){ref-type="table-fn"}
  Self-rated sexual health                            36.2                                              54.5                            0.63 (0.52--0.77)[e](#T3FN5){ref-type="table-fn"}   0.69 (0.58--0.83)[e](#T3FN5){ref-type="table-fn"}   0.57 (0.47--0.69)[e](#T3FN5){ref-type="table-fn"}
  Self-rated physical health                          44.7                                              68.1                            0.49 (0.40--0.60)[e](#T3FN5){ref-type="table-fn"}   0.95 (0.79--1.14)                                   0.62 (0.51--0.76)[e](#T3FN5){ref-type="table-fn"}
  Treatment satisfaction                              65.2                                              73.1                            0.73 (0.59--0.91)[e](#T3FN5){ref-type="table-fn"}   0.72 (0.59--0.87)[e](#T3FN5){ref-type="table-fn"}   0.57 (0.47--0.70)[e](#T3FN5){ref-type="table-fn"}
  Met treatment needs                                 68.7                                              68.5                            0.96 (0.78--1.18)                                   0.74 (0.61--0.89)[e](#T3FN5){ref-type="table-fn"}   0.68 (0.55--0.83)[e](#T3FN5){ref-type="table-fn"}
  Positive outlook for longevity                      42.5                                              49.8                            0.85 (0.70--1.04)                                   0.38 (0.31--0.46)[e](#T3FN5){ref-type="table-fn"}   0.47 (0.39--0.57)[e](#T3FN5){ref-type="table-fn"}
  **Reporting virologic suppression (n = 1,536)**                                                                                                                                                                                               
  Self-rated overall health                           48.7                                              65.0                            0.65 (0.51--0.83)[e](#T3FN5){ref-type="table-fn"}   0.61 (0.49--0.76)[e](#T3FN5){ref-type="table-fn"}   0.74 (0.59--0.93)[e](#T3FN5){ref-type="table-fn"}
  Self-rated mental health                            53.9                                              63.1                            0.75 (0.59--0.95)[e](#T3FN5){ref-type="table-fn"}   0.72 (0.58--0.89)[e](#T3FN5){ref-type="table-fn"}   0.55 (0.44--0.68)[e](#T3FN5){ref-type="table-fn"}
  Self-rated sexual health                            38.6                                              55.0                            0.75 (0.59--0.95)[e](#T3FN5){ref-type="table-fn"}   0.61 (0.49--0.75)[e](#T3FN5){ref-type="table-fn"}   0.60 (0.48--0.75)[e](#T3FN5){ref-type="table-fn"}
  Self-rated physical health                          49.0                                              71.5                            0.53 (0.42--0.68)[e](#T3FN5){ref-type="table-fn"}   0.75 (0.60--0.93)[e](#T3FN5){ref-type="table-fn"}   0.68 (0.54--0.86)[e](#T3FN5){ref-type="table-fn"}
  Treatment satisfaction                              69.5                                              73.5                            0.75 (0.58--0.98)[e](#T3FN5){ref-type="table-fn"}   0.67 (0.53--0.85)[e](#T3FN5){ref-type="table-fn"}   0.52 (0.41--0.66)[e](#T3FN5){ref-type="table-fn"}
  Met treatment needs                                 72.2                                              68.1                            1.05 (0.81--1.36)                                   0.65 (0.52--0.82)[e](#T3FN5){ref-type="table-fn"}   0.74 (0.58--0.94)[e](#T3FN5){ref-type="table-fn"}
  Positive outlook for longevity                      49.5                                              56.1                            0.93 (0.74--1.18)                                   0.37 (0.30--0.45)[e](#T3FN5){ref-type="table-fn"}   0.56 (0.45--0.70)[e](#T3FN5){ref-type="table-fn"}
  **Not reporting virologic suppression (n = 576)**                                                                                                                                                                                             
  Self-rated overall health                           41.8                                              55.4                            0.73 (0.50--1.07)                                   0.75 (0.52--1.09)                                   0.59 (0.40--0.87)[e](#T3FN5){ref-type="table-fn"}
  Self-rated mental health                            31.0                                              62.3                            0.37 (0.25--0.54)[e](#T3FN5){ref-type="table-fn"}   1.35 (0.93--1.98)                                   0.48 (0.32--0.71)[e](#T3FN5){ref-type="table-fn"}
  Self-rated sexual health                            30.6                                              53.1                            0.44 (0.29--0.66)[e](#T3FN5){ref-type="table-fn"}   0.88 (0.60--1.30)                                   0.54 (0.36--0.82)[e](#T3FN5){ref-type="table-fn"}
  Self-rated physical health                          34.7                                              57.7                            0.48 (0.32--0.70)[e](#T3FN5){ref-type="table-fn"}   1.62 (1.11--2.36)[e](#T3FN5){ref-type="table-fn"}   0.61 (0.41--0.90)[e](#T3FN5){ref-type="table-fn"}
  Treatment satisfaction                              55.2                                              71.8                            0.63 (0.43--0.94)[e](#T3FN5){ref-type="table-fn"}   0.92 (0.62--1.36)                                   0.73 (0.48--1.11)
  Met treatment needs                                 60.4                                              69.5                            0.70 (0.47--1.04)                                   0.99 (0.67--1.45)                                   0.51 (0.34--0.78)[e](#T3FN5){ref-type="table-fn"}
  Positive outlook for longevity                      26.5                                              30.8                            0.94 (0.62--1.42)                                   0.26 (0.17--0.41)[e](#T3FN5){ref-type="table-fn"}   0.31 (0.21--0.48)[e](#T3FN5){ref-type="table-fn"}

Abbreviations: AOR, adjusted odds ratio; CI, confidence interval.

Countries included in study were Argentina, Austria, Australia, Belgium, Brazil, Canada, Chile, China, France, Germany, Ireland, Italy, Japan, Mexico, Netherlands, Poland, Portugal, Russia, South Korea, Spain, Switzerland, Taiwan, United Kingdom, and United States.

Polypharmacy was defined as taking 5 or more pills per day for HIV or non-HIV conditions or taking medicines currently for 5 or more conditions, including HIV/AIDS. For the cognitive proxy (perceived overmedication), we used a set of 6 questions that assessed respondents' anxieties regarding short-, medium-, and long-term effects from their current HIV medicines, including worries about long-term side effects, having to take increasingly more medicines, potential interactions with other medications, impact on body and/or body shape, impact on overall health and well-being, and unknown long-term impact. Being worried about at least 5 of these items was subjectively classified as acute awareness on the part of the respondent of the number of medicines they were taking. For the behavioral proxy (cut-down attempt), participants were classified as having taken deliberate efforts to reduce the number/impact of medicines they were taking if they skipped taking their HIV medicines in the past 30 days because they were concerned about short- or long-term side effects of medicines or if they completely switched medicines to reduce the number of medicines taken.

Self-reported virologic suppression was defined as a response of "undetectable" or "suppressed" versus "detectable," "unsuppressed," "I don't know," or "prefer not to say" to the question, "What is your most recent viral load?"

Adjusted odds ratios for the different outcomes were computed in separate logistic regression models, controlling for age, duration of disease, geographic region, comorbidities, urbanicity, education, and sexual orientation.

Significant at *P* \< .05.

![Comparison of prevalence of subjective measures of overall well-being by polypharmacy status, people from 24 countries who were living with HIV (N = 2,112), Positive Perspectives survey. Polypharmacy was defined as taking 5 or more pills per day for HIV or non-HIV conditions, or taking medicines currently for 5 or more conditions, including HIV. All differences between people with a report of polypharmacy compared with those not reporting polypharmacy were significant at *P* \< .05. Brackets indicate standard errors.](PCD-17-E22s01){#F1}

After adjusting for potential confounders, including presence of comorbidities, people reporting polypharmacy had significantly worse overall health outcomes and lower odds of reporting virologic control and treatment satisfaction than those who did not. Those reporting polypharmacy compared with those not reporting it in the overall population had lower odds of self-rated optimal overall health (AOR = 0.64; 95% CI, 0.53--0.78), optimal mental health (AOR = 0.58; 95% CI, 0.48--0.71), optimal sexual health (AOR = 0.63; 95% CI, 0.52--0.77), and optimal physical health (AOR = 0.49; 95% CI, 0.41--0.60) ([Table 3](#T3){ref-type="table"}). Analyses of other measures of overall well-being revealed consistent results. People reporting polypharmacy had significantly lower odds, independent of presence of comorbidities, of treatment satisfaction (AOR = 0.73; 95% CI, 0.59--0.91) and self-reported virologic control (AOR = 0.54; 95% CI, 0.42--0.70). Stratified analyses on self-reported virologic control status showed that regardless of virologic control, people taking more medicines had less favorable health outcomes and treatment satisfaction ([Figure 1](#F1){ref-type="fig"}). The association between polypharmacy and measures of overall well-being was, however, stronger among those not reporting than reporting virologic control. For example, polypharmacy reduced the odds of reporting optimal mental health by 25% (AOR = 0.75; 95% CI, 0.59--0.95) among those reporting virologic control, but by 63% among those reporting virologic failure (AOR = 0.37; 95% CI, 0.25--0.54) ([Table 3](#T3){ref-type="table"}).

**Polypharmacy and its associations with new concerns toward medications**. Among people who were 2 or more years post HIV/AIDS diagnosis (n = 1,624), a comparison of treatment priorities at time of initiating ART versus priorities at the time of our survey revealed that the 2 concerns with the largest absolute increase in perceived importance were minimizing the long-term impact of HIV treatment (16.1 percentage points difference) and reducing the number of medications in ART (15.0 percentage points difference) ([Figure 2](#F2){ref-type="fig"}). Prevalence of new ART-related concerns among people who were 2 or more years post HIV/AIDS diagnosis and who did not report those concerns at ART initiation was as follows: risk of side effects (46.6%, 337 of 724); risk of long-term effects, including potential damage to organs such as kidneys or bones (45.5%, 411 of 904); risk of transmission to a partner (40.4%, 347 of 860); perceived need to reduce number of medications in ART (35.7%, 378 of 1,059); risk of drug--drug interactions (29.4%, 323 of 1,100); management of HIV-related illnesses (29.4%, 221 of 751); flexibility with meals or time taken (29.0%, 300 of 1,035); availability/accessibility (19.5%, 226 of 1,162); cost (13.9%, 172 of 1,239); and childbearing (10.2%, 143 of 1,401). Polypharmacy and current experience of side effects were significantly associated with new concerns regarding drug--drug interactions, and side effects ([Table 4](#T4){ref-type="table"}). Within adjusted analyses, PLHIV reporting polypharmacy had significantly increased odds of having new concerns about the risk of drug--drug interactions (AOR = 1.32; 95% CI, 1.02--1.71), and of side effects (AOR = 1.31, 95% CI, 1.02--1.68). PLHIV who perceived themselves as overmedicated also had higher odds of reporting new concerns about the following: number of medications in their ART and the need to keep them at a minimum (AOR = 1.54; 95% CI, 1.22--1.95), risk of drug--drug interactions (AOR = 1.38; 95% CI, 1.08--1.77), flexibility of dosing (AOR = 1.41; 95% CI, 1.10--1.82), and availability of ART (AOR = 1.39; 95% CI, 1.05--1.85). PLHIV who were experiencing side effects from their ART at the time of our survey had higher odds of reporting new concerns regarding risk of side effects (AOR = 1.53; 95% CI, 1.20--1.96) and concerns about viral suppression and disease transmission to a partner (AOR = 1.29; 95% CI, 1.01--1.65).

![Perceived treatment priorities at initiation of antiretroviral therapy and at the time of the Positive Perspectives survey among treatment experienced people from 24 countries who had been living with HIV for 2 years or longer (n = 1,624), 2019.](PCD-17-E22s02){#F2}

###### Experience of Side Effects, Polypharmacy[a](#T4FN1){ref-type="table-fn"}, Perceived Overmedication, and Cut-Down Attempts as Predictors of New Treatment Concerns[b](#T4FN2){ref-type="table-fn"} Among People Living With HIV for 2 Years or Longer (N = 1,624), Positive Perspectives Study, 2019[c](#T4FN3){ref-type="table-fn"}

  New Treatment Concern                                  Report of Experiencing Side Effects From ART, AOR (95% CI)   Polypharmacy, AOR (95% CI)                          Perceived Overmedication, AOR (95% CI)[d](#T4FN4){ref-type="table-fn"}   Cut-Down Attempts, AOR (95% CI)
  ------------------------------------------------------ ------------------------------------------------------------ --------------------------------------------------- ------------------------------------------------------------------------ ---------------------------------------------------
  Keep number of HIV medicines in ART to a minimum       1.10 (0.86--1.39)                                            1.26 (0.99--1.61)                                   1.54 (1.22--1.95)[e](#T4FN5){ref-type="table-fn"}                        0.92 (0.72--1.18)
  Minimize the long-term impact of HIV treatment         1.06 (0.84--1.33)                                            1.15 (0.91--1.45)                                   1.12 (0.89--1.40)                                                        0.82 (0.64--1.04)
  Compatibility with other medications                   1.09 (0.84--1.40)                                            1.32 (1.02--1.71)[e](#T4FN5){ref-type="table-fn"}   1.38 (1.08--1.77)                                                        0.84 (0.65--1.10)
  Allow me to have children                              1.31 (0.92--1.86)                                            1.03 (0.71--1.49)                                   1.38 (0.98--1.96)                                                        1.69 (1.16--2.44)[e](#T4FN5){ref-type="table-fn"}
  Viral suppression to prevent transmission to partner   1.29 (1.01--1.65)[e](#T4FN5){ref-type="table-fn"}            1.27 (0.99--1.63)                                   1.21 (0.95--1.54)                                                        0.90 (0.70--1.16)
  Flexibility (eg, time of day, with or without food)    1.08 (0.83--1.40)                                            1.40 (1.07--1.83)[e](#T4FN5){ref-type="table-fn"}   1.41 (1.10--1.82)                                                        0.87 (0.67--1.15)
  Minimal side effects                                   1.53 (1.20--1.96)[e](#T4FN5){ref-type="table-fn"}            1.31 (1.02--1.68)[e](#T4FN5){ref-type="table-fn"}   1.14 (0.90--1.46)                                                        0.81 (0.62--1.04)
  Availability of ART in my public health facility       1.14 (0.85--1.52)                                            1.34 (0.99--1.79)                                   1.39 (1.05--1.85)                                                        1.18 (0.87--1.59)
  Medication cost                                        0.91 (0.66--1.27)                                            1.34 (0.96--1.86)                                   1.09 (0.79--1.50)                                                        1.24 (0.89--1.73)
  Manage HIV symptoms or illnesses                       1.01 (0.76--1.36)                                            1.22 (0.90--1.64)                                   1.17 (0.88--1.56)                                                        1.14 (0.84--1.54)

Abbreviations: AOR, adjusted odds ratio; ART, antiretroviral therapy; CI, confidence interval.

Polypharmacy was defined as taking 5 or more pills per day for HIV or non-HIV conditions, or currently taking medicines for 5 or more conditions, including HIV.

A new treatment concern was one that was not deemed important by the survey respondent at ART initiation but was considered a priority at the time of this study.

Among treatment experienced people living with HIV. Separate logistic regression models were fitted for the different outcomes, controlling for age, geographic region, urbanicity, education, and sexual orientation.

To assess perceived overmedication (cognitive proxy), we used a set of 6 questions that assessed respondents' anxieties regarding their current HIV medications: 1) short-, medium-, and long-term effects of including worries about long-term side effects; 2) having to take more and more medications; 3) potential interactions with other medications; 4) effect on body and/or body shape; 5) effect on overall health and well-being; 6) unknown long-term effects. Being worried on at least 5 of these issues was subjectively classified as the respondent's acute awareness of the number of medications they were taking. To assess cut-down attempt (behavioral proxy) we classified people as having taken deliberate efforts to reduce the number and effects of their HIV medications if they skipped taking their medications in the past 30 days because they were concerned about short- or long-term side effects or if they completely switched medications to reduce the number taken.

Significant at *P* \< .05.

**Determinants of openness to taking ART with fewer medicines.** Most (75.1%) PLHIV were aware of the number of medicines their ART medications contained ([Table 2](#T2){ref-type="table"}). Of all participants, 73.1% were open to switching to an ART that contained fewer medications as long as their viral load was suppressed. Willingness to switch was highest among men who have sex with men (77.9%, 742 of 953) vs men who have sex with women (63.8%, 268 of 420) and women who have sex with men (63.8%, 263 of 369) (*P* \< .001); people aged 50 or older (79.9%, 518 of 648) compared with those younger than 50 (70.1%, 1,026 of 1,464) (*P* \< .001); those living with HIV the longest (ie, diagnosed pre-2010 \[76.4%\] compared with those diagnosed between 2010 and 2016 \[70.1%, 564 of 805\] or 2017 and 2019 \[72.5%, 354 of 488\]) (*P* = .014), and those living in metropolitan areas (76.3%, 893 of 1,170) compared with nonmetropolitan areas (69.1%, 651 of 942) (*P* \< .001). Furthermore, willingness to switch increased with increasing number of comorbidities and was 68.8%, 73.3%, and 77.9% among those reporting 0, 1, or 2 or more comorbidities, respectively (*P* \< .001). Interest in taking fewer medicines increased with increasing number of concomitant medications; 70.3% (850 of 1,209) of people on ART only and no other medication indicated willingness to switch to ART with fewer medicines. This percentage increased to 77.8 (326 of 419) among those with 1 medication in addition to ART and to 76.0% (368 of 484) among those with 2 or more other medications.

Overall, 73.4% (n = 1,550) of study participants had ever switched ART since starting treatment. Top reasons for switching among those who had ever switched were to reduce the severity or frequency of side effects (45.3%) and to reduce the number of pills (35.0%) or number of medicines (26.8%) taken. Other specified reasons were because of ineffectiveness or resistance (24.4%), drug--drug interactions (18.6%), or cost (14.8%). Of all participants, 32.0% reported skipping their ART on at least one occasion in the past 30 days out of concerns for immediate or long-term side effects.

In total, 44.3% of participants experienced side effects from their ART, and 41.8% of all participants felt HIV had a negative effect on their life. Specific ART-related concerns among the overall sample included risks of long-term effects of HIV medicines (66.6%) and the risk for drug--drug interactions (48.5%) ([Table 2](#T2){ref-type="table"}).

Discussion
==========

Polypharmacy was strongly associated with poorer health-related quality of life outcomes among PLHIV, independent of the presence of existing comorbidities. These findings were consistent both among those reporting and not reporting virologic suppression, although prevalence estimates of poor health outcomes were significantly higher among the latter. The finding of significant associations even among those reporting viral suppression supports the idea espoused in the fourth 90 of the UNAID's 90--90-90 framework that quality of life is not about just virologic control. In our study, one of the most common reasons PLHIV switched ART in the past was to reduce the number of medicines or pills they had to take, and 2 in 3 PLHIV were willing to switch to an ART with fewer medications as long as their viral load was suppressed. Concurrent use of multiple medications may considerably increase risk of drug--drug interactions, especially among people with concomitant medications ([@R22]--[@R24]), and this concern was well reflected in our study. Recent studies have established that the number of drug--drug interactions increases with the number of medications ([@R22]--[@R24]). Most non-HIV conditions reported by PLHIV in our study were chronic conditions largely found in the general population, such as mental health conditions, hypertension, and hypercholesterolemia, which may require long-term management with medications. But even besides concerns regarding the risk of drug--drug interactions, increased use of medicines was associated with poor treatment satisfaction among PLHIV in our study.

Our findings emphasize that treatment needs are constantly evolving; continuous communication between patients and providers is therefore critical. For example, PLHIV experiencing side effects from their ART at the time of the study had significantly higher odds of reporting worries about the risk of side effects as a new concern relative to when they started ART. The most common new concerns among PLHIV were the risks of side effects, long-term effects, disease transmission to a partner, and the number of medicines in ART. Number of medicines in ART, along with concerns about long-term effects of HIV medicines, had the largest absolute increase as important treatment considerations at the time of our survey relative to time of ART initiation among treatment experienced PLHIV. These evolutions in patient preferences with age or onset of other comorbidities highlight the need to constantly re-evaluate current and future treatment needs of PLHIV on the basis of patient-specific risks of comorbidities, co-existing conditions, concomitant medications, and patient concerns about treatment. A proactive treatment plan that considers the totality of a patient's current treatments and risks can result in a more holistic care that optimizes patient well-being.

Health-related quality of life outcomes are harder to quantify as measures of success, and most clinicians have limited power over upstream factors that affect overall well-being, such as socio-economic status. However, our study demonstrates the role of drug treatment on well-being within the context of increased medicines and how providers can positively affect care. By assessing patients holistically, considering their treatment needs and concerns, and streamlining treatments where appropriate, clinicians may contribute to improving patients' health-related quality of life. Alleviating anxiety through regular and continued communication and education may also reduce the worries and concerns reported in this study.

Our study suggests that patients were willing to switch to treatments with fewer medications, despite more than 2 in 3 reporting treatment satisfaction. Regardless of a patient's current viral load, constant review and assessment of treatment plans may be beneficial because patient needs and understanding of their medication evolve over time. Health care providers should be encouraged to simplify treatments where possible, discuss patients' treatment concerns, and share decision making with them, as well as provide them with information on newer treatments that may be beneficial to them.

HIV specialist clinicians can work holistically as part of a multidisciplinary team to address the various treatment-related concerns, worries, and anxieties identified in our study, especially among patients at greatest risk of receiving fragmented care, including older people, those with multiple disorders, those living in poverty, the uninsured, and patients in rural areas. The metrics for evaluating successful disease management, should focus not only on clinical endpoints, but also on patient-oriented outcomes and treatment satisfaction to ensure overall wellbeing. Enhanced and sustained efforts in this regard will ensure progress toward the National HIV/AIDS strategy, a 5-year plan developed by the US department of Health and Human Services in response to the HIV epidemic ([@R19]).

A strength of our study is its use of a standardized protocol in 24 countries. To the best of our knowledge, this is one of the largest studies of PLHIV to assess patient-centered outcomes, including aspirations and attitudes toward treatment. Nonetheless, our study had limitations. First, the cross-sectional design limited any causal inferences. Second, self-reported measures such as viral load may have resulted in misclassification. For example, we classified both people reporting their viral load as detectable or unsuppressed and those who reported they did not know or who refused to answer as virally failing, which may result in misclassification of those with indeterminate status; however, the extent of bias is likely small because of the small percentage this group comprised. Third, the sample may be biased because of nonprobabilistic sampling and the use of a web-based questionnaire. Finally, only a limited number of countries were included. For example, although Africa bears the largest HIV burden in the world, no country in sub-Saharan Africa was included in our analyses.

Approximately 2 in 5 PLHIV surveyed reported polypharmacy, which was significantly associated with poorer health-related quality of life outcomes. A high number of study participants also reported being worried about taking more medicines as they grew older; many were open to switching to ART with fewer medicines, especially people with kidney and bone disorders. Clinicians should consider addressing patient concerns and worries along with treatment. Doing so may help improve health-related quality of life among PLHIV and accelerate progress toward meeting UNAID's fourth 90.

Financial support for primary data collection came from ViiV Healthcare. Fielding of the survey was conducted by Ipsos Healthcare. Data analyses and editorial services were performed by Zatum LLC and reviewed by Constantine Vardavas, MD, MPH, PhD. We especially acknowledge participants and patient advocacy groups that supported enrollment. No copyrighted materials were included in this article.

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors\' affiliated institutions.

*Suggested citation for this article:* Okoli C, de los Rios P, Eremin A, Brough G, Young B, Short D. Relationship Between Polypharmacy and Quality of Life Among People in 24 Countries Living With HIV. Prev Chronic Dis 2020;17:190359. DOI: <https://doi.org/10.5888/pcd17.190359>.
